Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT05710848
Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Phase 1/2 · United States · 20 sites
Registry update: 27 May 2026
NCT06287541
Recruiting
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
Not applicable · China · 1 site
Registry update: 1 Mar 2024
NCT05912816
Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Phase 2 · China · 1 site
Registry update: 9 Dec 2025
NCT06441110
Recruiting
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Phase 3 · China · 1 site
Registry update: 4 Jun 2024
NCT07494864
Recruiting
Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
Not applicable · Switzerland · 1 site
Registry update: 27 Mar 2026
NCT07403630
Recruiting
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Not applicable · Italy · 2 sites
Registry update: 17 Feb 2026
NCT06026189
Recruiting
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Not applicable · Netherlands · 1 site
Registry update: 6 Sept 2023
NCT05646485
Recruiting
Bladder Cancer Screening Trial
Not applicable · United States · 1 site
Registry update: 1 May 2026
NCT06167057
Recruiting
POST URS Chemotherapy Instillation
Not applicable · Israel · 10 sites
Registry update: 20 Dec 2023
NCT06218433
Recruiting
Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Not applicable · Canada, Finland · 2 sites
Registry update: 18 Nov 2025
NCT05726786
Recruiting
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Phase 3 · Switzerland · 4 sites
Registry update: 9 Dec 2025
NCT05790850
Recruiting
Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
Not applicable · United States · 1 site
Registry update: 16 Dec 2024
NCT05672615
Recruiting
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Not applicable · United States · 1 site
Registry update: 4 Nov 2026
NCT05706129
Recruiting
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/2 · Australia, Belgium, France · 13 sites
Registry update: 11 Aug 2026
NCT05733000
Recruiting
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Phase 2 · United States · 1 site
Registry update: 10 Mar 2023
NCT06511648
Recruiting
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Phase 2 · Spain, France, United Kingdom, Italy · 23 sites
Registry update: 19 Dec 2025
Conflicting statuses (not updated in the registry for 10 months)
NCT05786716
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Phase 2/3 · United Kingdom · 27 sites
Registry update: 2 Dec 2025
NCT05715684
Recruiting
Patient-Centered Surgical Prehabilitation
Not applicable · United States · 2 sites
Registry update: 30 Sept 2026
NCT05002556
Recruiting
AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Not applicable · France · 44 sites
Registry update: 30 Apr 2026
NCT05503797
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom, Italy, South Korea, Netherlands, Norway, Sweden, United States · 70 sites
Registry update: 27 Jul 2026

Ordered by registry start date. Freshness and sponsorship never change the order.